Letter to the Editor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

In response to the article “Oncology takes blame for rising healthcare cost” (page 1, July 2009), I would like to direct Oncology News International readers to two articles on the “Win-Win” initiative. The full text articles are available online for free at:

In response to the article “Oncology takes blame for rising healthcare cost” (page 1, July 2009), I would like to direct Oncology News International readers to two articles on the “Win-Win” initiative. The full text articles are available online for free at:

“Breast Cancer Systemic Therapy: The need for more economically sustainable scientific strategies in the world,” Breast Care 3:434–438, 2008, www.karger.com/brc

“The ‘Win-Win’ initiative: A global, scientifically based approach to resource-sparing treatment for systemic breast cancer therapy,” World J Surg Oncol 7:44, 2009, www.wjso.com/content/7/1/44.

-Prof. Ahmed Elzawawy president, International Campaign for Establishment and Development of Oncology Centres, and director, South and East Mediterranean College of Oncology, Port Said, Egypt

Articles in this issue
Industry Watch
Letter to the Editor
Novel chemoRT regimen ups survival in pancreatic ca
Low expression of MSH2 protein predicts survival in NSCLC
Prostate cancer pilot program stresses patient-oriented care
Quality of life deficits offset benefits of preoperative rectal radiation therapy
CT distinguishes liver cancer mets from lung primary
Prostate cancer patients seek out mind-body care
Who's News
Panitumumab plus FOLFIRI bests FOLFIRI alone as second-line colon ca Rx
A crisis in metastatic breast ca development
Avastin shows active anti-tumor activity in brain cancer
NATCH trial finds no benefit for chemo Rx plus surgery
Lung ca staging stirs debate about noncontrast imaging
Women with metastatic breast cancer fight for a place in the ‘pink parade’
Recent Videos
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Related Content
Phase 1 data related to CLN-049 for patients with acute myeloid leukemia will be presented at the 2025 ASH Annual Meeting and Exposition.

FDA Grants Fast Track Designation to Novel FLT3/CD3 Bispecific in R/R AML

Russ Conroy
December 2nd 2025
Article

Phase 1 data related to CLN-049 for patients with acute myeloid leukemia will be presented at the 2025 ASH Annual Meeting and Exposition.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.

JANX007 Displays Encouraging Safety/Efficacy in Metastatic CRPC

Roman Fabbricatore
December 2nd 2025
Article

Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.

Zanidatamab Shows Meaningful Benefit in HER2+ Biliary Tract Cancer

Russ Conroy
December 1st 2025
Article

Findings from the HERIZON-BTC-01 trial support HER2 as a valid therapeutic target in biliary tract cancer.

ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma

ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma

Ariana Pelosci
December 1st 2025
Article

Edward Chu, MD, a member of the gastrointestinal editorial advisory board, died of glioblastoma in November.